

# Andrea Doria

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7443364/publications.pdf>

Version: 2024-02-01

313  
papers

19,758  
citations

10956

71  
h-index

15218

126  
g-index

326  
all docs

326  
docs citations

326  
times ranked

16112  
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.5	1,265
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	2.9	1,098
3	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.5	868
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
5	Accelerated Atherosclerosis in Autoimmune Rheumatic Diseases. <i>Circulation</i> , 2005, 112, 3337-3347.	1.6	484
6	Anti-inflammatory and immunosuppressive drugs and reproduction. <i>Arthritis Research and Therapy</i> , 2006, 8, 209.	1.6	469
7	Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: A prospective study of 100 women. <i>Arthritis and Rheumatism</i> , 2001, 44, 1832-1835.	6.7	435
8	Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1833-1838.	0.5	350
9	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	5.8	314
10	Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 1016-1027.	2.9	287
11	Long-Term Prognosis and Causes of Death in Systemic Lupus Erythematosus. <i>American Journal of Medicine</i> , 2006, 119, 700-706.	0.6	278
12	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.5	268
13	The kaleidoscope of glucocorticoid effects on immune system. <i>Autoimmunity Reviews</i> , 2011, 10, 305-310.	2.5	225
14	Novel Biomarkers in Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 385-400.	1.8	204
15	Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: An international meta-analysis. <i>Arthritis and Rheumatism</i> , 2006, 54, 312-324.	6.7	201
16	Infections and autoimmunity: the multifaceted relationship. <i>Journal of Leukocyte Biology</i> , 2009, 87, 385-395.	1.5	188
17	Genes, epigenetic regulation and environmental factors: Which is the most relevant in developing autoimmune diseases?. <i>Autoimmunity Reviews</i> , 2012, 11, 604-609.	2.5	188
18	Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 519-525.	0.4	186

#	ARTICLE	IF	CITATIONS
19	Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 2117-2122.	0.5	181
20	Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1083-1086.	0.5	178
21	Autoimmunity and Anti-TNF- $\alpha$ Agents. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 559-569.	1.8	150
22	Overlap connective tissue disease syndromes. <i>Autoimmunity Reviews</i> , 2013, 12, 363-373.	2.5	150
23	The clinical features, diagnosis and classification of dermatomyositis. <i>Journal of Autoimmunity</i> , 2014, 48-49, 122-127.	3.0	148
24	A Randomized Pilot Trial Comparing Cyclosporine and Azathioprine for Maintenance Therapy in Diffuse Lupus Nephritis over Four Years. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 925-932.	2.2	146
25	SLE diagnosis and treatment: When early is early. <i>Autoimmunity Reviews</i> , 2010, 10, 55-60.	2.5	134
26	Brief Report: Successful pregnancies but a higher risk of preterm births in patients with systemic sclerosis: An Italian multicenter study. <i>Arthritis and Rheumatism</i> , 2012, 64, 1970-1977.	6.7	134
27	Novel aspects of Sjögren's syndrome in 2012. <i>BMC Medicine</i> , 2013, 11, 93.	2.3	134
28	Calprotectin in rheumatic diseases. <i>Experimental Biology and Medicine</i> , 2017, 242, 859-873.	1.1	131
29	Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 104-110.	0.5	131
30	Development and validation of a new algorithm for attribution of neuropsychiatric events in systemic lupus erythematosus. <i>Rheumatology</i> , 2015, 54, 891-898.	0.9	129
31	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1558-1566.	0.5	127
32	Th2 immune deviation induced by pregnancy: The two faces of autoimmune rheumatic diseases. <i>Reproductive Toxicology</i> , 2006, 22, 234-241.	1.3	126
33	Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. <i>Rheumatology</i> , 2010, 49, 2370-2374.	0.9	121
34	Galectin-3 in autoimmunity and autoimmune diseases. <i>Experimental Biology and Medicine</i> , 2015, 240, 1019-1028.	1.1	120
35	Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1318-1325.	0.5	119
36	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	1.0	118

#	ARTICLE	IF	CITATIONS
37	New therapeutic strategies in systemic lupus erythematosus management. <i>Nature Reviews Rheumatology</i> , 2019, 15, 30-48.	3.5	118
38	Autoantibodies in Polymyositis and Dermatomyositis. <i>Current Rheumatology Reports</i> , 2013, 15, 335.	2.1	114
39	Emerging and critical issues in the pathogenesis of lupus. <i>Autoimmunity Reviews</i> , 2013, 12, 523-536.	2.5	114
40	Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002, 47, 202-209.	6.7	113
41	Anti-Mi-2 antibodies. <i>Autoimmunity</i> , 2005, 38, 79-83.	1.2	112
42	Pregnancy and reproduction in autoimmune rheumatic diseases. <i>Rheumatology</i> , 2011, 50, 657-664.	0.9	112
43	Optimizing outcome in SLE: treating-to-target and definition of treatment goals. <i>Autoimmunity Reviews</i> , 2014, 13, 770-777.	2.5	108
44	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, etc.) <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50 4</i>	2.5	107
45	Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 115-123.	1.5	107
46	Permeability changes induced by 130 GHz pulsed radiation on cationic liposomes loaded with carbonic anhydrase. <i>Bioelectromagnetics</i> , 2007, 28, 587-598.	0.9	106
47	Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study. <i>Autoimmunity Reviews</i> , 2016, 15, 983-993.	2.5	105
48	Long-Term Outcomes in Difficult-to-Treat Patients With Recurrent Pericarditis. <i>American Journal of Cardiology</i> , 2006, 98, 267-271.	0.7	104
49	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. <i>Autoimmunity Reviews</i> , 2019, 18, 93-106.	2.5	101
50	Lupus nephritis: clinical presentations and outcomes in the 21st century. <i>Rheumatology</i> , 2020, 59, v39-v51.	0.9	100
51	Human papillomavirus vaccine and systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2013, 32, 1301-1307.	1.0	98
52	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	1.1	97
53	Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 51, 989-995.	6.7	95
54	Autoantibodies in lupus: Culprits or passive bystanders?. <i>Autoimmunity Reviews</i> , 2012, 11, 596-603.	2.5	95

#	ARTICLE	IF	CITATIONS
55	Myositis autoantibodies and clinical phenotypes. <i>Autoimmunity Highlights</i> , 2014, 5, 69-75.	3.9	95
56	Serpins, Immunity and Autoimmunity: Old Molecules, New Functions. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 45, 267-280.	2.9	94
57	Mycophenolate mofetil: What is its place in the treatment of autoimmune rheumatic diseases?. <i>Autoimmunity Reviews</i> , 2007, 6, 190-195.	2.5	93
58	Anti-SAE antibodies in autoimmune myositis: Identification by unlabelled protein immunoprecipitation in an Italian patient cohort. <i>Journal of Immunological Methods</i> , 2012, 384, 128-134.	0.6	90
59	Treatment Strategy in Fibromyalgia Syndrome: Where Are We Now?. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 353-365.	1.6	89
60	Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients. <i>Rheumatology</i> , 2012, 51, 157-168.	0.9	89
61	Fetal outcome and recommendations of pregnancies in lupus nephritis in the 21st century. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 6-12.	3.0	89
62	Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 365-371.	0.5	88
63	SERPINB3, apoptosis and autoimmunity. <i>Autoimmunity Reviews</i> , 2009, 9, 108-112.	2.5	87
64	Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. <i>Journal of Autoimmunity</i> , 2018, 86, 1-8.	3.0	86
65	Environment and systemic lupus erythematosus: An overview. <i>Autoimmunity</i> , 2005, 38, 465-472.	1.2	85
66	Predictors of maternal and fetal complications in SLE patients: a prospective study. <i>Immunologic Research</i> , 2014, 60, 170-176.	1.3	84
67	The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 562-565.	0.5	83
68	Pregnancy and vasculitis: A systematic review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, A447-A459.	2.5	81
69	Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 996-1002.	0.5	81
70	Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study. <i>Journal of Autoimmunity</i> , 2016, 74, 194-200.	3.0	80
71	Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease. <i>PLoS ONE</i> , 2013, 8, e71458.	1.1	79
72	Antinuclear antibodies in recurrent idiopathic pericarditis: Prevalence and clinical significance. <i>International Journal of Cardiology</i> , 2009, 136, 289-293.	0.8	75

#	ARTICLE	IF	CITATIONS
73	Recurrent pericarditis: Autoimmune or autoinflammatory?. <i>Autoimmunity Reviews</i> , 2012, 12, 60-65.	2.5	73
74	Five-Year Follow-Up by Transesophageal Echocardiographic Studies in Primary Antiphospholipid Syndrome. <i>American Journal of Cardiology</i> , 2005, 96, 574-579.	0.7	72
75	Thrombotic Risk Factors In Primary Antiphospholipid Syndrome. <i>Stroke</i> , 2005, 36, 1490-1494.	1.0	71
76	Autoantibodies against Protective Molecules—C1q, C-reactive Protein, Serum Amyloid P, Mannose-Binding Lectin, and Apolipoprotein A1. <i>Annals of the New York Academy of Sciences</i> , 2007, 1108, 227-239.	1.8	71
77	Annual direct medical cost of active systemic lupus erythematosus in five European countries. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 154-160.	0.5	68
78	Infections, rheumatism and autoimmunity: The conflicting relationship between humans and their environment. <i>Autoimmunity Reviews</i> , 2008, 8, 1-4.	2.5	67
79	Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?. <i>Journal of Rheumatology</i> , 2005, 32, 213-5.	1.0	67
80	Systemic lupus erythematosus: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000793.	1.8	66
81	Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2020, 99, 496-504.	1.5	66
82	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010, 9, 849-852.	2.5	65
83	JAK/STAT/PKC $\gamma$ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. <i>Immunologic Research</i> , 2014, 58, 61-69.	1.3	65
84	IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. <i>Experimental Biology and Medicine</i> , 2019, 244, 42-51.	1.1	65
85	Estrogens in Pregnancy and Systemic Lupus Erythematosus. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 247-256.	1.8	63
86	Muscle biopsy features of idiopathic inflammatory myopathies and differential diagnosis. <i>Autoimmunity Highlights</i> , 2014, 5, 77-85.	3.9	63
87	Increased Neural Sympathetic Activation in Fibromyalgia Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 109-117.	1.8	62
88	Inflammation and Accelerated Atherosclerosis: Basic Mechanisms. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 355-362.	0.8	61
89	Cyclosporine (CsA) in lupus nephritis: assessing the evidence. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 15-20.	0.4	61
90	Prognosis of scleroderma renal crisis: a long-term observational study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 4398-4403.	0.4	61

#	ARTICLE	IF	CITATIONS
91	Does seronegative antiphospholipid syndrome really exist?. <i>Autoimmunity Reviews</i> , 2012, 11, 581-584.	2.5	60
92	Esophageal motor function in primary Sjögren's syndrome: correlation with dysphagia and xerostomia. <i>Digestive Diseases and Sciences</i> , 1997, 42, 113-118.	1.1	59
93	Preventive strategies in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2008, 7, 192-197.	2.5	59
94	Anti-Jo-1 Antibodies. <i>Autoimmunity</i> , 2005, 38, 73-78.	1.2	58
95	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2071-2074.	0.5	58
96	Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. <i>Arthritis and Rheumatology</i> , 2020, 72, 1314-1324.	2.9	58
97	Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 856-63.	0.4	56
98	Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 449-56.	0.4	55
99	Therapy of scleroderma renal crisis: State of the art. <i>Autoimmunity Reviews</i> , 2018, 17, 882-889.	2.5	53
100	Anti-Ku antibodies in connective tissue diseases: clinical and serological evaluation of 14 patients. <i>Journal of Rheumatology</i> , 2002, 29, 1393-7.	1.0	53
101	Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation. <i>Arthritis Research and Therapy</i> , 2010, 12, R52.	1.6	52
102	Prolactin and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 189-198.	2.9	52
103	Recurrent pericarditis: Infectious or autoimmune?. <i>Autoimmunity Reviews</i> , 2008, 8, 44-47.	2.5	51
104	Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: A two-year prospective observational study. <i>Joint Bone Spine</i> , 2014, 81, 421-425.	0.8	51
105	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016, 3, e000163.	1.1	51
106	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007, 6, 529-536.	2.5	50
107	Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1077-1083.	0.5	49
108	Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: An Italian multicentric study and review of the literature. <i>Autoimmunity Reviews</i> , 2012, 11, 815-820.	2.5	48

#	ARTICLE	IF	CITATIONS
109	Pregnancy and autoimmunity: Maternal treatment and maternal disease influence on pregnancy outcome. <i>Autoimmunity Reviews</i> , 2005, 4, 423-428.	2.5	47
110	Systemic Lupus Erythematosus, Atherosclerosis, and Autoantibodies. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 351-361.	1.8	46
111	Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. <i>Immunologic Research</i> , 2013, 56, 362-370.	1.3	46
112	Systemic vasculitis and pregnancy: A multicenter study on maternal and neonatal outcome of 65 prospectively followed pregnancies. <i>Autoimmunity Reviews</i> , 2015, 14, 686-691.	2.5	46
113	Autoinflammatory Features in Gouty Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1880.	1.0	46
114	Polymyositis“dermatomyositis and infections. <i>Autoimmunity</i> , 2006, 39, 191-196.	1.2	45
115	Clinical and pathologic considerations of the qualitative and quantitative aspects of lupus nephritogenic autoantibodies: A comprehensive review. <i>Journal of Autoimmunity</i> , 2016, 69, 1-11.	3.0	45
116	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	2.5	44
117	Influence of coping skills on health-related quality of life in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006, 55, 427-433.	6.7	43
118	Role of galectin-3 in autoimmune and non-autoimmune nephropathies. <i>Autoimmunity Reviews</i> , 2017, 16, 34-47.	2.5	43
119	Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. <i>Autoimmunity Reviews</i> , 2005, 4, 144-152.	2.5	42
120	Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis. <i>Journal of Autoimmunity</i> , 2016, 74, 94-105.	3.0	42
121	The use of Tween 20 in immunoblotting assays for the detection of autoantibodies in connective tissue diseases. <i>Journal of Immunological Methods</i> , 2000, 239, 1-11.	0.6	41
122	Work productivity is associated with disease activity and functional ability in Italian patients with early axial spondyloarthritis: an observational study from the SPACE cohort. <i>Arthritis Research and Therapy</i> , 2016, 18, 265.	1.6	41
123	Immune“Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA“DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum. <i>Arthritis and Rheumatology</i> , 2017, 69, 1090-1099.	2.9	41
124	Pulmonary arterial hypertension in connective tissue disorders: Pathophysiology and treatment. <i>Experimental Biology and Medicine</i> , 2019, 244, 120-131.	1.1	41
125	Erosive hand osteoarthritis: latest findings and outlook. <i>Nature Reviews Rheumatology</i> , 2022, 18, 171-183.	3.5	41
126	Anti-double-stranded DNA antibodies in the healthy elderly: Prevalence and characteristics. <i>Journal of Clinical Immunology</i> , 1990, 10, 300-303.	2.0	40



#	ARTICLE	IF	CITATIONS
127	Bisphosphonates in patients with autoimmune rheumatic diseases: Can they be used in women of childbearing age?. <i>Autoimmunity Reviews</i> , 2010, 9, 547-552.	2.5	40
128	Passive transfer of affinity-purified anti-heart autoantibodies (AHA) from sera of patients with myocarditis induces experimental myocarditis in mice. <i>International Journal of Cardiology</i> , 2015, 179, 166-177.	0.8	40
129	Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. <i>Clinical Rheumatology</i> , 2019, 38, 2843-2850.	1.0	39
130	Commercial blot assays in the diagnosis of systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2009, 8, 645-649.	2.5	38
131	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	1.8	38
132	Refractory pemphigus foliaceus and Behçet's disease successfully treated with tocilizumab. <i>Immunologic Research</i> , 2013, 56, 390-397.	1.3	37
133	Can we manage lupus nephritis without chronic corticosteroids administration?. <i>Autoimmunity Reviews</i> , 2018, 17, 4-10.	2.5	37
134	New insights in myositis-specific autoantibodies. <i>Current Opinion in Rheumatology</i> , 2018, 30, 614-622.	2.0	37
135	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
136	Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvasculature in the joints of psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1903-1912.	1.0	36
137	Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1571-1580.	1.0	36
138	Advances in the diagnosis and classification of systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1309-1320.	1.3	36
139	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
140	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNECT. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
141	Medium-/Long-Term Effects of a Specific Exercise Protocol Combined with Patient Education on Spine Mobility, Chronic Fatigue, Pain, Aerobic Fitness and Level of Disability in Fibromyalgia. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	34
142	Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 331-343.	2.9	34
143	Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. <i>Rheumatology</i> , 2020, 59, 1591-1598.	0.9	34
144	Exploring the complex relationships between infections and autoimmunity. <i>Autoimmunity Reviews</i> , 2008, 8, 89-91.	2.5	33

#	ARTICLE	IF	CITATIONS
145	PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2015, 49, 217-226.	2.9	33
146	Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 754-759.	0.4	33
147	Hyperferritinemia is Associated with Serologic Antiphospholipid Syndrome in SLE Patients. <i>Clinical Reviews in Allergy and Immunology</i> , 2013, 44, 23-30.	2.9	32
148	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017, 16, 650-657.	2.5	32
149	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. <i>RMD Open</i> , 2021, 7, e001519.	1.8	32
150	Successful use of rituximab in a young patient with immunoglobulin G4-related disease and refractory scleritis. <i>Joint Bone Spine</i> , 2014, 81, 190-192.	0.8	31
151	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007, 6, 553-558.	2.5	30
152	Immunization with pentraxin 3 (PTX3) leads to anti-PTX3 antibody production and delayed lupus-like nephritis in NZB/NZW F1 mice. <i>Journal of Autoimmunity</i> , 2016, 74, 208-216.	3.0	30
153	Mixed connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000783.	1.8	30
154	Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 943-950.	0.5	30
155	Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, 50-6.	0.4	30
156	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.4	30
157	Diagnostic Tests for Antiribosomal P Protein Antibodies: A Comparative Evaluation of Immunoblotting and ELISA Assays. <i>Journal of Autoimmunity</i> , 2002, 19, 71-77.	3.0	29
158	Ex Vivo Signaling Protein Mapping in T Lymphocytes in the Psoriatic Arthritis Joints. <i>Journal of rheumatology Supplement, The</i> , 2015, 93, 48-52.	2.2	29
159	Pulmonary involvement in antisynthetase syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 603-610.	2.0	29
160	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. <i>European Journal of Internal Medicine</i> , 2020, 78, 17-25.	1.0	29
161	Canakinumab for the treatment of adult-onset Still's disease. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 129-138.	1.3	29
162	Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1568-1574.	0.5	29

#	ARTICLE	IF	CITATIONS
163	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000786.	1.8	28
164	Cutting Edge Issues in Polymyositis. Clinical Reviews in Allergy and Immunology, 2011, 41, 179-189.	2.9	26
165	Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: A newsworthy association. Autoimmunity Reviews, 2019, 18, 177-183.	2.5	26
166	Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmunity Reviews, 2010, 9, 161-164.	2.5	25
167	Effect of pregnancy on serum cytokines in SLE patients. Arthritis Research and Therapy, 2012, 14, R66.	1.6	25
168	Health Technology Assessment of Belimumab: A New Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. BioMed Research International, 2014, 2014, 1-9.	0.9	25
169	“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. Joint Bone Spine, 2019, 86, 475-481.	0.8	25
170	Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort. Rheumatology, 2020, 59, 2272-2281.	0.9	25
171	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. Lancet Rheumatology, The, 2021, 3, e166-e168.	2.2	25
172	Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3225-3227.e2.	2.0	23
173	Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLISS-LN). Results from a large, nationwide, multicentric cohort. Journal of Autoimmunity, 2021, 124, 102729.	3.0	23
174	How I treat idiopathic patients with inflammatory myopathies in the clinical practice. Autoimmunity Reviews, 2017, 16, 999-1007.	2.5	22
175	The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities. Autoimmunity Reviews, 2021, 20, 102785.	2.5	22
176	In-/off-label use of biologic therapy in systemic lupus erythematosus. BMC Medicine, 2014, 12, 30.	2.3	21
177	Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: a literature review. Expert Opinion on Drug Safety, 2015, 14, 1373-1385.	1.0	21
178	Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints. Clinical Rheumatology, 2017, 36, 391-399.	1.0	21
179	IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000787.	1.8	21
180	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. Rheumatology, 2020, 59, 3731-3736.	0.9	21

#	ARTICLE	IF	CITATIONS
181	Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. <i>Rheumatology</i> , 2021, 60, 5610-5619.	0.9	21
182	SERPINB3 expression on B-cell surface in autoimmune diseases and hepatitis C virus-related chronic liver infection. <i>Experimental Biology and Medicine</i> , 2012, 237, 793-802.	1.1	20
183	Celiac Disease Prevalence Is Increased in Primary Sjögren's Syndrome and Diffuse Systemic Sclerosis: Lessons from a Large Multi-Center Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 540.	1.0	20
184	An update on serum biomarkers to assess axial spondyloarthritis and to guide treatment decision. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2093427.	1.2	20
185	Lymphocyte immunophenotyping in inflammatory myositis: a review. <i>Current Opinion in Rheumatology</i> , 2021, 33, 522-528.	2.0	20
186	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	0.9	20
187	The Relevance of Autoantigen Source and Cutoff Definition in Antichromatin (Nucleosome) Antibody Immunoassays. <i>Annals of the New York Academy of Sciences</i> , 2005, 1050, 176-184.	1.8	19
188	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	1.8	19
189	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, 112.	1.6	19
190	Rheumatic and autoimmune thyroid disorders: A causal or casual relationship?. <i>Autoimmunity Reviews</i> , 2015, 14, 57-63.	2.5	18
191	Self-reported flares are predictors of radiographic progression in rheumatoid arthritis patients in 28-joint disease activity score remission: a 24-month observational study. <i>Arthritis Research and Therapy</i> , 2016, 18, 89.	1.6	18
192	Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome. <i>Autoimmunity Highlights</i> , 2020, 11, 8.	3.9	18
193	Autoantibody testing in patients with myositis: clinical accuracy of a multiparametric line immunoassay. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 176-177.	0.4	18
194	Autoinflammatory diseases: How to put the fire inside the body out?. <i>Autoimmunity Reviews</i> , 2012, 12, 1-4.	2.5	17
195	Autoinflammatory Mechanisms in Crystal-Induced Arthritis. <i>Frontiers in Medicine</i> , 2020, 7, 166.	1.2	17
196	Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. <i>Rheumatology</i> , 2022, 61, 688-695.	0.9	17
197	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	2.2	17
198	The periprosthetic capsule and connective tissue diseases: a piece in the puzzle of autoimmune/autoinflammatory syndrome induced by adjuvants. <i>Experimental Biology and Medicine</i> , 2012, 237, 1117-1122.	1.1	16

#	ARTICLE	IF	CITATIONS
199	When to use belimumab in SLE. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 737-740.	1.3	16
200	Preclinical and early systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101422.	1.4	16
201	Nonimmune mechanisms in idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2020, 32, 515-522.	2.0	16
202	Spine and Sacroiliac Joints Lesions on Magnetic Resonance Imaging in Early Axial-Spondyloarthritis During 24-Months Follow-Up (Italian Arm of SPACE Study). <i>Frontiers in Immunology</i> , 2020, 11, 936.	2.2	16
203	Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF $\pm$ , anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. <i>Clinical Rheumatology</i> , 2021, 40, 4569-4580.	1.0	16
204	From old concerns to new advances and personalized medicine in lupus: The end of the tunnel is approaching. <i>Journal of Autoimmunity</i> , 2016, 74, 1-5.	3.0	15
205	Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study. <i>Rheumatology</i> , 2022, 61, 3657-3666.	0.9	15
206	Methotrexate in early rheumatoid arthritis: Is the anchor drug still holding?. <i>Autoimmunity Reviews</i> , 2022, 21, 103031.	2.5	15
207	Do we believe in non-radiographic axial spondyloarthritis? A debate. <i>Autoimmunity Reviews</i> , 2021, 20, 102703.	2.5	14
208	Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 219.	1.6	14
209	Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. <i>Rheumatology</i> , 2022, 61, 3309-3316.	0.9	14
210	Atherosclerosis and Lupus: What We Know and What We Should Know. <i>Journal of Rheumatology</i> , 2009, 36, 2380-2382.	1.0	13
211	Phase-Sensitive Reflective Imaging Device in the mm-wave and Terahertz Regions. <i>Journal of Infrared, Millimeter, and Terahertz Waves</i> , 2009, 30, 1351.	1.2	13
212	Grade and location of power Doppler are predictive of damage progression in rheumatoid arthritis patients in clinical remission by anti-tumour necrosis factor $\pm$ . <i>Rheumatology</i> , 2017, 56, 1320-1325.	0.9	13
213	The new targeted therapy in systemic lupus erythematosus: Is the glass half-full or half-empty?. <i>Autoimmunity Reviews</i> , 2017, 16, 1119-1124.	2.5	13
214	Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 472-489.	2.9	13
215	Primary prevention of systemic lupus erythematosus. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 576-577.	3.2	12
216	Pseudotumoral calcinosis in systemic sclerosis: Data from systematic literature review and case series from two referral centres. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1339-1347.	1.6	12

#	ARTICLE	IF	CITATIONS
217	Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion. <i>Rheumatology</i> , 2021, 60, 1313-1320.	0.9	12
218	Hyperinflammation after anti-SARS-CoV-2 mRNA/DNA vaccines successfully treated with anakinra: Case series and literature review. <i>Experimental Biology and Medicine</i> , 2022, 247, 338-344.	1.1	12
219	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
220	Mycophenolate Mofetil in Lupus Glomerulonephritis: Effectiveness and Tolerability. <i>Annals of the New York Academy of Sciences</i> , 2007, 1110, 516-524.	1.8	11
221	Expression of myositis specific autoantigens during post-natal myogenesis. <i>Neurological Research</i> , 2008, 30, 145-148.	0.6	11
222	Targeting BAFF/BLyS in lupus: is the glass half-full or half-empty?: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 321-322.	0.5	11
223	Clinical outcomes and predictors of maternal and fetal complications in pregnancies of patients with systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 617-627.	1.3	11
224	Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110406.	1.2	11
225	Cell Stress Response in Skeletal Muscle Myofibers. <i>Annals of the New York Academy of Sciences</i> , 2006, 1069, 472-476.	1.8	10
226	The Immunogenicity of Branded and Biosimilar Infliximab in Rheumatoid Arthritis According to Th9-Related Responses. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2127.	1.8	10
227	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019, 10, 29.	2.2	10
228	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: A prospective long-term follow-up. <i>Autoimmunity</i> , 2008, 41, 87-91.	1.2	9
229	Anti-polymer antibodies are inversely correlated with pain and fatigue severity in patients with fibromyalgia syndrome. <i>Autoimmunity</i> , 2008, 41, 74-79.	1.2	9
230	An observational multicentre study on the efficacy and safety of assisted reproductive technologies in women with rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz005.	0.3	9
231	Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. <i>Journal of Nephrology</i> , 2021, 34, 389-398.	0.9	9
232	Belimumab: a step forward in the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 563-573.	1.4	9
233	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.5	9
234	Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 158-161.	0.4	9

#	ARTICLE	IF	CITATIONS
235	SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy. <i>Frontiers in Pharmacology</i> , 2021, 12, 660123.	1.6	8
236	Clinical profile and direct medical cost of care of adults presenting with systemic lupus erythematosus in Italy. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 375-84.	0.4	8
237	Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis. <i>Lupus Science and Medicine</i> , 2022, 9, e000689.	1.1	8
238	Acute immunomodulatory changes during controlled ovarian stimulation: evidence from the first trial investigating the short-term effects of estradiol on biomarkers and B cells involved in autoimmunity. <i>Journal of Assisted Reproduction and Genetics</i> , 2015, 32, 1765-1772.	1.2	7
239	Bronchiolitis obliterans organizing pneumonia in patients with autoimmune rheumatic diseases. <i>Immunologic Research</i> , 2015, 61, 97-103.	1.3	7
240	SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype. <i>Frontiers in Immunology</i> , 2018, 9, 2081.	2.2	7
241	Squamous cell carcinoma antigen-IgM (SCCA-IgM) is associated with interstitial lung disease in systemic sclerosis. <i>Joint Bone Spine</i> , 2020, 87, 331-335.	0.8	7
242	Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: Insights from renal ultrastructural findings. <i>Journal of Autoimmunity</i> , 2020, 111, 102443.	3.0	7
243	The Genetic Contribution to Drug Response in Spondyloarthritis: A Systematic Literature Review. <i>Frontiers in Genetics</i> , 2021, 12, 703911.	1.1	7
244	IgG anti-Pentraxin 3 antibodies are a novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2021, 124, 102725.	3.0	7
245	Progress in Biological Therapies for Adult-Onset Still's Disease. <i>Biologics: Targets and Therapy</i> , 2022, Volume 16, 21-34.	3.0	7
246	Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210903.	1.2	7
247	Controversies in rheumatism and autoimmunity. <i>Autoimmunity Reviews</i> , 2012, 11, 555-557.	2.5	6
248	Drugs in induction and treatment of idiopathic inflammatory myopathies. <i>Autoimmunity Highlights</i> , 2014, 5, 95-100.	3.9	6
249	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography With Magnetic Resonance for Diagnosing Adult-Onset Still's Disease. <i>Frontiers in Medicine</i> , 2020, 7, 544412.	1.2	6
250	Renal disorders in rheumatologic diseases: the spectrum is changing (Part 1: connective tissue) <i>TJ ETQq0 0 0 rgBT / Overlock 10 Tf 50 14</i>	0.9	6
251	Higher Ventricular-Arterial Coupling Derived from Three-Dimensional Echocardiography Is Associated with a Worse Clinical Outcome in Systemic Sclerosis. <i>Pharmaceutics</i> , 2021, 14, 646.	1.7	6
252	Effect of pathogenic crystals on the production of pro- and anti-inflammatory cytokines by different leukocyte populations. <i>Immunobiology</i> , 2021, 226, 152042.	0.8	6

#	ARTICLE	IF	CITATIONS
253	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 240-250.	2.9	6
254	Monotherapy is a relevant option in rheumatoid arthritis treatment: a literature review. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 862-871.	0.4	6
255	Remission in SLE: the duration depends on multiple factors, including the definition. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, e77-e77.	0.5	5
256	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	1.3	5
257	Efficacy and Safety of Ultrasound-Guided Intra-articular Glucocorticoid Injection in Erosive Hand Osteoarthritis. <i>Pain Medicine</i> , 2021, 22, 1229-1232.	0.9	5
258	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. <i>Rheumatology</i> , 2022, 61, 743-755.	0.9	5
259	The burden of systemic sclerosis in Switzerland – the Swiss systemic sclerosis EUSTAR cohort. <i>Swiss Medical Weekly</i> , 2021, 151, w20528.	0.8	5
260	Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis. <i>Autoimmunity Reviews</i> , 2022, 21, 103018.	2.5	5
261	Organ specific-autoantibodies: Their role as markers and predictors of disease. <i>Autoimmunity</i> , 2008, 41, 1-10.	1.2	4
262	Unresolved and critical issues in autoimmune rheumatic diseases. <i>Autoimmunity Reviews</i> , 2017, 16, 1093-1095.	2.5	4
263	Response to: “SLE-DAS: ready for routine use” by Mathew <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e117-e117.	0.5	4
264	Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients. <i>Arthritis Research and Therapy</i> , 2021, 23, 134.	1.6	4
265	Estimated glomerular filtration rate is a marker of mortality in the European Scleroderma Trials and Research Group (EUSTAR) database. <i>Rheumatology</i> , 2021, 61, 213-222.	0.9	4
266	Psoriasis and imaging progression in early axial spondyloarthritis: results from a 48-month follow-up (Italian arm of SPACE study). <i>Rheumatology</i> , 2022, 61, 2375-2387.	0.9	4
267	Premature coronary disease in systemic lupus. <i>New England Journal of Medicine</i> , 2004, 350, 1571-5; author reply 1571-5.	13.9	4
268	Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 158-161.	0.4	4
269	Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2022, 9, 852162.	1.2	4
270	Health-related quality of life in patients with mixed connective tissue disease: a comparison with matched systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 66-70.	0.4	4



#	ARTICLE	IF	CITATIONS
271	Impact of low-dose acetylsalicylic acid on pregnancy outcome in systemic lupus erythematosus: results from a multicentre study. <i>Lupus Science and Medicine</i> , 2022, 9, e000714.	1.1	4
272	Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018, 57, .	0.9	3
273	FP070HUMAN PARIETAL EPITHELIAL CELLS EXPRESS TUBULAR PROTEIN UPTAKE SYSTEM IN VIVO. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i71-i72.	0.4	3
274	Response to: "Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort"™, by Hassan <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e52-e52.	0.5	3
275	Response to: "Performance of the systemic lupus erythematosus disease activity score (SLE-DAS) in a Latin American population"™ by Rodríguez-González <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e159-e159.	0.5	3
276	Baseline characteristics of systemic lupus erythematosus patients included in the Lupus Italian Registry of the Italian Society for Rheumatology. <i>Lupus</i> , 2021, 30, 1233-1243.	0.8	3
277	SARS-CoV-2 Infection in Spondyloarthritis Patients Treated With Biotechnological Drugs: A Study on Serology. <i>Frontiers in Immunology</i> , 2021, 12, 682850.	2.2	3
278	Physician's global assessment is often useful in SLE, but not always: the case of clinical remission. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-217611.	0.5	3
279	The Management of Systemic Lupus Erythematosus (SLE) Patients in Remission. <i>Israel Medical Association Journal</i> , 2017, 19, 454-458.	0.1	3
280	Adherence in rheumatoid arthritis patients assessed with a validated Italian version of the 5-item Compliance Questionnaire for Rheumatology. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 915-922.	0.4	3
281	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3
282	Identification in synovial fluid of a new potential pathogenic player in arthropathies. <i>Experimental Biology and Medicine</i> , 2022, 247, 1061-1066.	1.1	3
283	Protective molecules and their cognate antibodies: new players in autoimmunity. <i>Autoimmunity Highlights</i> , 2010, 1, 63-72.	3.9	2
284	Special Electromagnetic Agents: From Cold Plasma to Pulsed Electromagnetic Radiation. , 2017, , 109-154.		2
285	Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion. <i>Autoimmunity Reviews</i> , 2018, 17, 1-3.	2.5	2
286	Biological Effects of 25 to 150 GHz Radiation After In Vitro Exposure of Human Fibroblasts: a Comparison of Experimental Results. <i>Journal of Infrared, Millimeter, and Terahertz Waves</i> , 2018, 39, 899-911.	1.2	2
287	Renal disorders in rheumatologic diseases: the spectrum is changing (part 2. Arthridides). <i>Journal of Nephrology</i> , 2020, 34, 1081-1090.	0.9	2
288	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 62, 346-353.	2.9	2

#	ARTICLE	IF	CITATIONS
289	Health-Related Quality of Life in Patients With ANCA-Associated Vasculitis and Sinonasal Involvement. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e89-e94.	0.5	2
290	Biologic therapy in relapsing polychondritis: navigating between options. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 661-671.	1.4	2
291	Cardiac Involvement in Systemic Lupus Erythematosus. <i>Handbook of Systemic Autoimmune Diseases</i> , 2003, 1, 145-161.	0.1	1
292	Adalimumab in Psoriatic Arthritis. <i>Drugs</i> , 2006, 66, 1497-1499.	4.9	1
293	Antigen Preparation for Immunological Studies in Systemic Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 193-202.	1.8	1
294	Disease Activity Indices and Prognosis of Systemic Lupus Erythematosus. <i>Rare Diseases of the Immune System</i> , 2016, , 199-211.	0.1	1
295	Immediate treatment with tumour necrosis factor inhibitors in synthetic disease-modifying anti-rheumatic drugs-naïve patients with rheumatoid arthritis: results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018, 57, vii32-vii41.	0.9	1
296	THU0267â€¦THE SLE DISEASE ACTIVITY SCORE (SLE-DAS) ENABLES ACCURATE DEFINITIONS OF SLE REMISSION AND LDA AS ACHIEVABLE TARGETS IN DISEASE MANAGEMENT. , 2019, , .		1
297	Response to: â€œRemission or low disease activity as a target in systemic lupus erythematosusâ€™ by Ugarte-Gil et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, e4-e4.	0.5	1
298	What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts. <i>Lupus Science and Medicine</i> , 2021, 8, e000506.	1.1	1
299	The Influence of Dietary Intervention in Connective Tissue Diseases: Evidence from Randomized Clinical Trials. <i>Rheumato</i> , 2021, 1, 5-16.	0.2	1
300	Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 188-194.	0.4	1
301	Renal involvement at baseline can predict major renal relapse in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 201-206.	0.4	1
302	Skin ulcers in systemic sclerosis: correlation with clinical phenotype in a monocentric cohort from the north-east of Italy. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 125, 148-153.	0.4	1
303	Pregnancy in Rheumatoid Arthritis, Sjögren Syndrome and Other Rare Autoimmune Rheumatic Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2005, 4, 77-93.	0.1	0
304	Offspring of Women with Systemic Autoimmune Diseases: Fetal and Neonatal Complications and Inheritance of Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , 2005, 4, 111-121.	0.1	0
305	Progression de l'arthrose chez les patients ayant un rhumatisme psoriasique malgré un traitement par anti-TNF-alpha: Étude prospective observationnelle de 2Ans. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014, 81, 395-399.	0.0	0
306	028â€œLargest Genetic Study to Date in Sporadic Inclusion Body Myositis Confirms the Human Leukocyte Antigen as the Most Associated Region and Suggests a Role for C-C Chemokine Receptor Type 5. <i>Rheumatology</i> , 2016, , .	0.9	0

#	ARTICLE	IF	CITATIONS
307	039.â€fANTI-PENTRAXIN-3 AUTOANTIBODIES IN ANCA-ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
308	12â€œ...Belimumab helps lupus patients to achieve lupus targets. , 2020, , .		0
309	Le complexe antigÃªne de carcinome Ã  cellules squameuses-IgM (SCCA-IgM) est associÃ© Ã  la pneumopathie interstitielle diffuse dans la sclÃ©rodermie systÃ©mique. Revue Du Rhumatisme (Edition Francaise), 2020, 87, 472-476.	0.0	0
310	Infections and Polymyositis-Dermatomyositis. , 2004, , 583-590.		0
311	Comment on: Prevalence, outcome and management of patients with SLE and secondary antiphospholipid antibody syndrome after aPL seroconversion: reply. Rheumatology, 2021, 60, e115-e117.	0.9	0
312	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0
313	SjÃ¶rgren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. Clinical and Experimental Rheumatology, 2022, , .	0.4	0